{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:44:45Z","timestamp":1782708285052,"version":"3.54.5"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["706199"],"award-info":[{"award-number":["706199"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"publisher","award":["180017"],"award-info":[{"award-number":["180017"]}],"id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013123","name":"Fondation de la recherche en sant\u00e9 du Nouveau-Brunswick","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013123","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000240","name":"New Brunswick Innovation Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000240","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,7,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Clear cell renal cell carcinoma (ccRCC) is primarily driven by chromosome 3p loss and inactivation of the von Hippel-Lindau (\n                      <jats:italic>VHL<\/jats:italic>\n                      ) gene, which is frequently accompanied by chromosome 5q gain. However, the oncogenic contribution of 5q remains unclear. This study examines how 5q gain affects the expression of microRNAs implicated in ccRCC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Bioinformatic analyses were conducted to evaluate miRNAs associated with 5q gain and 3p loss. RT-qPCR validation was performed in tumour tissues and patient plasma. Mechanistic investigations integrated open-source ChIP-seq datasets and luciferase reporter assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      miR-1271-5p overexpression was significantly associated with both 5q gain and 3p loss and strongly correlated with its host gene, ARL10. RT-qPCR confirmed elevated levels of miR-1271-5p and\n                      <jats:italic>ARL10<\/jats:italic>\n                      in ccRCC tumours and increased circulating miR-1271-5p in patient plasma. Mechanistically, these upregulations resulted from\n                      <jats:italic>VHL<\/jats:italic>\n                      loss and subsequent HIF\u03b1 stabilisation. ChIP-seq datasets and luciferase assays demonstrated that HIF-1\u03b1, but not HIF-2\u03b1, directly binds within the intragenic region of\n                      <jats:italic>ARL10<\/jats:italic>\n                      . Importantly, this regulatory mechanism was specific to kidney cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Coordinated upregulation of miR-1271-5p and\n                      <jats:italic>ARL10<\/jats:italic>\n                      reflects key genomic events in ccRCC and is driven by kidney-specific HIF-1a activity. Our findings suggest their promise for early detection and disease monitoring.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-026-03399-w","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:13:35Z","timestamp":1776428015000},"page":"189-201","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kidney-specific HIF-1\u03b1-dependent ARL10\/miR-1271-5p overexpression in clear cell renal cell carcinoma"],"prefix":"10.1038","volume":"135","author":[{"given":"Patric M.","family":"Page","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Laperri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia A.","family":"Dastous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie E.","family":"Landry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick O.","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Pavic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7980-8736","authenticated-orcid":false,"given":"Sandra","family":"Turcotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"3399_CR1","unstructured":"SEER. SEER*Explorer: an interactive website for SEER cancer statistic [Internet]. 2025 [updated Apr 16]. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/."},{"key":"3399_CR2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","volume":"82","author":"B Ljungberg","year":"2022","unstructured":"Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: the 2022 update. Eur Urol. 2022;82:399\u2013410.","journal-title":"Eur Urol"},{"key":"3399_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.","journal-title":"Nat Rev Dis Primers"},{"key":"3399_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5489\/cuaj.7245","volume":"15","author":"C Canil","year":"2021","unstructured":"Canil C, Kapoor A, Basappa NS, Bjarnason G, Boss\u00e9 D, Dudani S, et al. Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Can Urol Assoc J. 2021;15:84\u201397.","journal-title":"Can Urol Assoc J"},{"key":"3399_CR5","first-page":"132","volume":"15","author":"R Sun","year":"2021","unstructured":"Sun R, Breau RH, Mallick R, Tanguay S, Pouliot F, Kapoor A, et al. Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: results from Canadian Kidney Cancer information system. Can Urol Assoc J. 2021;15:132\u20137.","journal-title":"Can Urol Assoc J"},{"key":"3399_CR6","doi-asserted-by":"publisher","first-page":"e035938","DOI":"10.1136\/bmjopen-2019-035938","volume":"10","author":"NS Vasudev","year":"2020","unstructured":"Vasudev NS, Wilson M, Stewart GD, Adeyoju A, Cartledge J, Kimuli M, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ Open. 2020;10:e035938.","journal-title":"BMJ Open"},{"key":"3399_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cell.2018.03.043","volume":"173","author":"S Turajlic","year":"2018","unstructured":"Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx Renal. Cell. 2018;173:595\u2013610.e11.","journal-title":"Cell"},{"key":"3399_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"CJ Creighton","year":"2013","unstructured":"Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA, Gordon Robertson A, et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43\u20139.","journal-title":"Nature"},{"key":"3399_CR9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883\u201392.","journal-title":"N Engl J Med"},{"key":"3399_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/ng.2891","volume":"46","author":"M Gerlinger","year":"2014","unstructured":"Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014;46:225\u201333.","journal-title":"Nat Genet"},{"key":"3399_CR11","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899\u2013905.","journal-title":"Nature"},{"key":"3399_CR12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1158\/2159-8290.CD-11-0098","volume":"1","author":"C Shen","year":"2011","unstructured":"Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, Signoretti S, et al. Genetic and functional studies implicate HIF1\u03b1 as a 14q kidney cancer suppressor gene. Cancer Discov. 2011;1:222\u201335.","journal-title":"Cancer Discov"},{"key":"3399_CR13","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/ng.2699","volume":"45","author":"Y Sato","year":"2013","unstructured":"Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013;45:860\u20137.","journal-title":"Nat Genet"},{"key":"3399_CR14","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.1059796","volume":"292","author":"P Jaakkola","year":"2001","unstructured":"Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292:468\u201372.","journal-title":"Science"},{"key":"3399_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1126\/science.1059817","volume":"292","author":"M Ivan","year":"2001","unstructured":"Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292:464\u20138.","journal-title":"Science"},{"key":"3399_CR16","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","volume":"92","author":"GL Wang","year":"1995","unstructured":"Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92:5510\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3399_CR17","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1182\/blood-2010-10-314427","volume":"117","author":"J Sch\u00f6del","year":"2011","unstructured":"Sch\u00f6del J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood. 2011;117:e207\u201317.","journal-title":"Blood"},{"key":"3399_CR18","doi-asserted-by":"publisher","first-page":"16767","DOI":"10.1074\/jbc.M901790200","volume":"284","author":"DR Mole","year":"2009","unstructured":"Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, et al. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem. 2009;284:16767\u201375.","journal-title":"J Biol Chem"},{"key":"3399_CR19","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","volume":"33","author":"GL Semenza","year":"2012","unstructured":"Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33:207\u201314.","journal-title":"Trends Pharmacol Sci"},{"key":"3399_CR20","doi-asserted-by":"crossref","unstructured":"Kaelin WG, Jr. Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer. J Clin Investig. 2022;132:e162480.","DOI":"10.1172\/JCI162480"},{"key":"3399_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.cell.2018.02.020","volume":"173","author":"TJ Mitchell","year":"2018","unstructured":"Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O\u2019Brien T, et al. Timing the Landmark events in the evolution of clear cell renal cell cancer: TRACERx Renal. Cell. 2018;173:611\u201323.e17.","journal-title":"Cell"},{"key":"3399_CR22","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ccr.2013.10.025","volume":"24","author":"L Li","year":"2013","unstructured":"Li L, Shen C, Nakamura E, Ando K, Signoretti S, Beroukhim R, et al. SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell. 2013;24:738\u201350.","journal-title":"Cancer Cell"},{"key":"3399_CR23","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1158\/1541-7786.MCR-16-0444","volume":"15","author":"Y Mitsui","year":"2017","unstructured":"Mitsui Y, Shiina H, Kato T, Maekawa S, Hashimoto Y, Shiina M, et al. Versican promotes tumor progression, metastasis and predicts poor prognosis in renal carcinoma. Mol Cancer Res. 2017;15:884\u201395.","journal-title":"Mol Cancer Res"},{"key":"3399_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/0008-5472.CAN-11-1698","volume":"72","author":"VR Dondeti","year":"2012","unstructured":"Dondeti VR, Wubbenhorst B, Lal P, Gordan JD, D\u2019Andrea K, Attiyeh EF, et al. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res. 2012;72:112\u201321.","journal-title":"Cancer Res"},{"key":"3399_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","volume":"173","author":"DP Bartel","year":"2018","unstructured":"Bartel DP. Metazoan MicroRNAs. Cell. 2018;173:20\u201351.","journal-title":"Cell"},{"key":"3399_CR26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.tibs.2010.03.009","volume":"35","author":"T Kawamata","year":"2010","unstructured":"Kawamata T, Tomari Y. Making RISC. Trends Biochem Sci. 2010;35:368\u201376.","journal-title":"Trends Biochem Sci"},{"key":"3399_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111528","volume":"138","author":"BM Hussen","year":"2021","unstructured":"Hussen BM, Hidayat HJ, Salihi A, Sabir DK, Taheri M, Ghafouri-Fard S. MicroRNA: a signature for cancer progression. Biomed Pharmacother. 2021;138:111528.","journal-title":"Biomed Pharmacother"},{"key":"3399_CR28","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ccr.2012.02.019","volume":"21","author":"O Mikhaylova","year":"2012","unstructured":"Mikhaylova O, Stratton Y, Hall D, Kellner E, Ehmer B, Drew AF, et al. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell. 2012;21:532\u201346.","journal-title":"Cancer Cell"},{"key":"3399_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4161\/cbt.27314","volume":"15","author":"B Gowrishankar","year":"2014","unstructured":"Gowrishankar B, Ibragimova I, Zhou Y, Slifker MJ, Devarajan K, Al-Saleem T, et al. MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther. 2014;15:329\u201341.","journal-title":"Cancer Biol Ther"},{"key":"3399_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03711-3","volume":"25","author":"PM Page","year":"2025","unstructured":"Page PM, Dastous SA, Richard PO, Pavic M, Nishimura T, Riazalhosseini Y, et al. MicroRNA profiling identifies VHL\/HIF-2\u03b1 dependent miR-2355-5p as a key modulator of clear cell Renal cell carcinoma tumor growth. Cancer Cell Int. 2025;25:71.","journal-title":"Cancer Cell Int"},{"key":"3399_CR31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrclinonc.2011.76","volume":"8","author":"MA Cortez","year":"2011","unstructured":"Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids\u2014the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8:467\u201377.","journal-title":"Nat Rev Clin Oncol"},{"key":"3399_CR32","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nrurol.2016.193","volume":"13","author":"A Fendler","year":"2016","unstructured":"Fendler A, Stephan C, Yousef GM, Kristiansen G, Jung K. The translational potential of microRNAs as biofluid markers of urological tumours. Nat Rev Urol. 2016;13:734\u201352.","journal-title":"Nat Rev Urol"},{"key":"3399_CR33","doi-asserted-by":"crossref","unstructured":"Chen Y, Chen L, Lun Aaron TL, Baldoni Pedro L, Smyth Gordon K. edgeR v4: powerful differential analysis of sequencing data with expanded functionality and improved support for small counts and larger datasets. Nucleic Acids Research. 2025;53:gkaf018.","DOI":"10.1093\/nar\/gkaf018"},{"key":"3399_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111652","volume":"41","author":"O Lombardi","year":"2022","unstructured":"Lombardi O, Li R, Halim S, Choudhry H, Ratcliffe PJ, Mole DR. Pan-cancer analysis of tissue and single-cell HIF-pathway activation using a conserved gene signature. Cell Rep. 2022;41:111652.","journal-title":"Cell Rep"},{"key":"3399_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55098-7","volume":"9","author":"V Schmid","year":"2019","unstructured":"Schmid V, Lafleur VN, Lombardi O, Li R, Salama R, Colli L, et al. Co-incidence of RCC-susceptibility polymorphisms with HIF cis-acting sequences supports a pathway tuning model of cancer. Sci Rep. 2019;9:18768.","journal-title":"Sci Rep"},{"key":"3399_CR36","doi-asserted-by":"crossref","unstructured":"Smythies JA, Sun M, Masson N, Salama R, Simpson PD, Murray E, et al. Inherent DNA-binding specificities of the HIF-1\u03b1 and HIF-2\u03b1 transcription factors in chromatin. EMBO Rep. 2019;20:e46401.","DOI":"10.15252\/embr.201846401"},{"key":"3399_CR37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/978-1-4939-3578-9_16","volume":"1418","author":"F Hahne","year":"2016","unstructured":"Hahne F, Ivanek R. Visualizing genomic data using Gviz and bioconductor. Methods Mol Biol. 2016;1418:335\u201351.","journal-title":"Methods Mol Biol"},{"key":"3399_CR38","doi-asserted-by":"publisher","first-page":"e27633","DOI":"10.2196\/27633","volume":"23","author":"A L\u00e1nczky","year":"2021","unstructured":"L\u00e1nczky A, Gy\u0151rffy B. Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): development and implementation. J Med Internet Res. 2021;23:e27633.","journal-title":"J Med Internet Res"},{"key":"3399_CR39","doi-asserted-by":"publisher","unstructured":"Zahm AM, Owens WS, Himes SR, Rondem KE, Fallon BS, Gormick AN, et al. Discovery and Validation of Context-Dependent Synthetic Mammalian Promoters. bioRxiv [Preprint]. 2023. Available from: https:\/\/doi.org\/10.1101\/2023.05.11.539703.","DOI":"10.1101\/2023.05.11.539703"},{"key":"3399_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/carcin\/bgl143","volume":"28","author":"T Shinojima","year":"2007","unstructured":"Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha. Carcinogenesis. 2007;28:529\u201336.","journal-title":"Carcinogenesis"},{"key":"3399_CR41","doi-asserted-by":"publisher","first-page":"C605","DOI":"10.1152\/ajpcell.00483.2018","volume":"316","author":"N Bouhamdani","year":"2019","unstructured":"Bouhamdani N, Comeau D, Cormier K, Turcotte S. STF-62247 accumulates in lysosomes and blocks late stages of autophagy to selectively target von Hippel-Lindau-inactivated cells. Am J Physiol Cell Physiol. 2019;316:C605\u201320.","journal-title":"Am J Physiol Cell Physiol"},{"key":"3399_CR42","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00404-020-05849-z","volume":"303","author":"D Wei","year":"2021","unstructured":"Wei D, Tian M, Fan W, Zhong X, Wang S, Chen Y, et al. Circular RNA circ_0000043 promotes endometrial carcinoma progression by regulating miR-1271-5p\/CTNND1 axis. Arch Gynecol Obstet. 2021;303:1075\u201387.","journal-title":"Arch Gynecol Obstet"},{"key":"3399_CR43","first-page":"5648","volume":"23","author":"Y Tian","year":"2019","unstructured":"Tian Y, Chen YY, Han AL. MiR-1271 inhibits cell proliferation and metastasis by targeting LDHA in endometrial cancer. Eur Rev Med Pharmacol Sci. 2019;23:5648\u201356.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3399_CR44","first-page":"2697","volume":"22","author":"HY Du","year":"2018","unstructured":"Du HY, Liu B. MiR-1271 as a tumor suppressor in breast cancer proliferation and progression via targeting SPIN1. Eur Rev Med Pharmacol Sci. 2018;22:2697\u2013706.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3399_CR45","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13046-019-1112-4","volume":"38","author":"BW Liu","year":"2019","unstructured":"Liu BW, Yu ZH, Chen AX, Chi JR, Ge J, Yu Y, et al. Estrogen receptor-\u03b1-miR-1271-SNAI2 feedback loop regulates transforming growth factor-\u03b2-induced breast cancer progression. J Exp Clin Cancer Res. 2019;38:109.","journal-title":"J Exp Clin Cancer Res"},{"key":"3399_CR46","doi-asserted-by":"publisher","first-page":"13255","DOI":"10.18632\/aging.103432","volume":"12","author":"J Shi","year":"2020","unstructured":"Shi J, Liu C, Chen C, Guo K, Tang Z, Luo Y, et al. Circular RNA circMBOAT2 promotes prostate cancer progression via a miR-1271-5p\/mTOR axis. Aging. 2020;12:13255\u201380.","journal-title":"Aging"},{"key":"3399_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02349-1","volume":"18","author":"Z Jiang","year":"2020","unstructured":"Jiang Z, Zhang Y, Chen X, Wang Y, Wu P, Wu C, et al. microRNA-1271 impedes the development of prostate cancer by downregulating PES1 and upregulating ER\u03b2. J Transl Med. 2020;18:209.","journal-title":"J Transl Med"},{"key":"3399_CR48","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1111\/1759-7714.13525","volume":"11","author":"G Fan","year":"2020","unstructured":"Fan G, Jiao J, Shen F, Chu F. Upregulation of lncRNA ZFAS1 promotes lung adenocarcinoma progression by sponging miR-1271-5p and upregulating FRS2. Thorac Cancer. 2020;11:2178\u201387.","journal-title":"Thorac Cancer"},{"key":"3399_CR49","first-page":"8384","volume":"24","author":"YS Lv","year":"2020","unstructured":"Lv YS, Wang C, Li LX, Han S, Li Y. Effects of circRNA_103993 on the proliferation and apoptosis of NSCLC cells through miR-1271\/ERG signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24:8384\u201393.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3399_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2020.135289","volume":"737","author":"YK Huang","year":"2020","unstructured":"Huang YK, Su YF, Lieu AS, Loh JK, Li CY, Wu CH, et al. MiR-1271 regulates glioblastoma cell proliferation and invasion by directly targeting the CAMKK2 gene. Neurosci Lett. 2020;737:135289.","journal-title":"Neurosci Lett"},{"key":"3399_CR51","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1007\/s11064-020-03131-x","volume":"45","author":"B Zhang","year":"2020","unstructured":"Zhang B, Chen J, Cui M, Jiang Y. LncRNA ZFAS1\/miR-1271-5p\/HK2 promotes glioma development through regulating proliferation, migration, invasion and apoptosis. Neurochem Res. 2020;45:2828\u201339.","journal-title":"Neurochem Res"},{"key":"3399_CR52","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.clinbiochem.2009.07.020","volume":"43","author":"TF Chow","year":"2010","unstructured":"Chow TF, Youssef YM, Lianidou E, Romaschin AD, Honey RJ, Stewart R, et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem. 2010;43:150\u20138.","journal-title":"Clin Biochem"},{"key":"3399_CR53","doi-asserted-by":"publisher","first-page":"e38298","DOI":"10.1371\/journal.pone.0038298","volume":"7","author":"S Osanto","year":"2012","unstructured":"Osanto S, Qin Y, Buermans HP, Berkers J, Lerut E, Goeman JJ, et al. Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PLoS ONE. 2012;7:e38298.","journal-title":"PLoS ONE"},{"key":"3399_CR54","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.21873\/invivo.13185","volume":"37","author":"S Grammatikaki","year":"2023","unstructured":"Grammatikaki S, Katifelis H, Stravodimos K, Bakolas E, Kavantzas N, Grigoriadou D, et al. The role of HIF1-related genes and non-coding RNAs expression in clear cell renal cell carcinoma. In Vivo. 2023;37:1103\u201310.","journal-title":"In Vivo"},{"key":"3399_CR55","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4033583","volume":"2022","author":"L Zhou","year":"2022","unstructured":"Zhou L, Ye J, Wen F, Yu H. Identification of novel prognostic signatures for clear cell renal cell carcinoma based on ceRNA network construction and immune infiltration analysis. Dis Markers. 2022;2022:4033583.","journal-title":"Dis Markers"},{"key":"3399_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-016-0565-8","volume":"15","author":"KK Brodaczewska","year":"2016","unstructured":"Brodaczewska KK, Szczylik C, Fiedorowicz M, Porta C, Czarnecka AM. Choosing the right cell line for renal cell cancer research. Mol Cancer. 2016;15:83.","journal-title":"Mol Cancer"},{"key":"3399_CR57","doi-asserted-by":"crossref","unstructured":"Brito C, Costa-Silva B, Barral DC, Pojo M. Unraveling the relevance of ARL GTPases in cutaneous melanoma prognosis through integrated bioinformatics analysis. Int J Mol Sci. 2021;22:9260.","DOI":"10.3390\/ijms22179260"},{"key":"3399_CR58","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","volume":"31","author":"L Fishbein","year":"2017","unstructured":"Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31:181\u201393.","journal-title":"Cancer Cell"},{"key":"3399_CR59","doi-asserted-by":"crossref","unstructured":"Quirion L, Robert A, Boulais J, Huang S, Bernal Astrain G, Strakhova R, et al. Mapping the global interactome of the ARF family reveals spatial organization in cellular signaling pathways. J Cell Sci. 2024;137:jcs262140.","DOI":"10.1242\/jcs.262140"},{"key":"3399_CR60","first-page":"1917","volume":"7","author":"Z Zhou","year":"2015","unstructured":"Zhou Z, Niu X, Li C, Sheng S, Lu S. Inhibition of the growth of non-small cell lung cancer by miRNA-1271. Am J Transl Res. 2015;7:1917\u201324.","journal-title":"Am J Transl Res"},{"key":"3399_CR61","first-page":"4363","volume":"17","author":"H Yao","year":"2019","unstructured":"Yao H, Sun Q, Zhu J. miR-1271 enhances the sensitivity of colorectal cancer cells to cisplatin. Exp Ther Med. 2019;17:4363\u201370.","journal-title":"Exp Ther Med"},{"key":"3399_CR62","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1111\/jog.14079","volume":"45","author":"Y Chen","year":"2019","unstructured":"Chen Y, Wang L, Zhou J. Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance. J Obstet Gynaecol Res. 2019;45:2243\u201354.","journal-title":"J Obstet Gynaecol Res"},{"key":"3399_CR63","first-page":"678","volume":"22","author":"F Xie","year":"2018","unstructured":"Xie F, Huang Q, Liu CH, Lin XS, Liu Z, Liu LL, et al. MiR-1271 negatively regulates AKT\/MTOR signaling and promotes apoptosis via targeting PDK1 in pancreatic cancer. Eur Rev Med Pharmacol Sci. 2018;22:678\u201386.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3399_CR64","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/onc.2010.427","volume":"30","author":"X He","year":"2011","unstructured":"He X, Wang J, Messing EM, Wu G. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness. Oncogene. 2011;30:535\u201347.","journal-title":"Oncogene"},{"key":"3399_CR65","doi-asserted-by":"publisher","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","volume":"1","author":"K Kondo","year":"2003","unstructured":"Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003;1:E83.","journal-title":"PLoS Biol"},{"key":"3399_CR66","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1128\/MCB.25.13.5675-5686.2005","volume":"25","author":"RR Raval","year":"2005","unstructured":"Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL, et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol. 2005;25:5675\u201386.","journal-title":"Mol Cell Biol"},{"key":"3399_CR67","doi-asserted-by":"crossref","unstructured":"Fernandes FG, Silveira HCS, J\u00fanior JNA, da Silveira RA, Zucca LE, C\u00e1rcano FM, et al. Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients. Int J Mol Sci. 2021;22:2265.","DOI":"10.3390\/ijms22052265"},{"key":"3399_CR68","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1200\/JCO.2007.15.8345","volume":"27","author":"T Klatte","year":"2009","unstructured":"Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009;27:746\u201353.","journal-title":"J Clin Oncol"},{"key":"3399_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-77774-9","volume":"10","author":"G Cochetti","year":"2020","unstructured":"Cochetti G, Cari L, Nocentini G, Maul\u00e0 V, Suvieri C, Cagnani R, et al. Detection of urinary miRNAs for diagnosis of clear cell renal cell carcinoma. Sci Rep. 2020;10:21290.","journal-title":"Sci Rep"},{"key":"3399_CR70","doi-asserted-by":"crossref","unstructured":"Cochetti G, Cari L, Maul\u00e0 V, Cagnani R, Paladini A, Del Zingaro M, et al. Validation in an independent cohort of MiR-122, MiR-1271, and MiR-15b as urinary biomarkers for the potential early diagnosis of clear cell renal cell carcinoma. Cancers. 2022;14:1112.","DOI":"10.3390\/cancers14051112"},{"key":"3399_CR71","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clgc.2023.07.002","volume":"22","author":"X Li","year":"2024","unstructured":"Li X, Wen Z, Li R, Lu C, Chen W, Chen X, et al. Profiling of serum miRNAs constructs a diagnostic 3-miRNA panel for clear-cell renal cell carcinoma. Clin Genitourin Cancer. 2024;22:23\u201332.","journal-title":"Clin Genitourin Cancer"},{"key":"3399_CR72","doi-asserted-by":"publisher","first-page":"186","DOI":"10.31083\/j.fbl2905186","volume":"29","author":"T He","year":"2024","unstructured":"He T, Lu C, Gong W, Ge Z, Li R, Li X, et al. miRNA-27b-3p, let-7f-5p and miRNA-142-5p can be used in a novel serum diagnostic panel for clear cell renal cell carcinoma. Front Biosci. 2024;29:186.","journal-title":"Front Biosci"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03399-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03399-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03399-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:02:12Z","timestamp":1782705732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03399-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,7,20]]}},"alternative-id":["3399"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03399-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors approved the final version of the manuscript and the submission to this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}